Status:
NOT_YET_RECRUITING
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Lead Sponsor:
CHA University
Conditions:
Biliary Tract Cancer
Eligibility:
All Genders
19+ years
Brief Summary
Biliary tract cancer (BTC) is a rare and heterogeneous disease with high incidence and mortality in Korea. Molecular profiling has enabled the identification of actionable alterations such as Isocitra...
Detailed Description
Biliary tract cancer (BTC) encompasses a rare and diverse group of tumors characterized by varying anatomical locations-including extrahepatic, intrahepatic, and gallbladder lesions. Therapeutic innov...
Eligibility Criteria
Inclusion
- Patients with histologically confirmed advanced or metastatic biliary tract cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer).
- Patients who meet one of the following conditions:
- Patients prior to initiation of first-line systemic chemotherapy, or
- Patients previously treated with systemic chemotherapy who can provide a blood sample immediately before starting subsequent therapy.
- Age ≥ 19 years at the time of enrollment.
- Willingness to provide a blood sample for ctDNA analysis.
Exclusion
- Patients who refuse to provide blood samples for ctDNA testing.
- Patients unable to provide written informed consent.
- Patients concurrently enrolled in a similar study within the same institution. Prior screening will be performed to prevent duplicate enrollment.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07142226
Start Date
September 1 2025
End Date
January 31 2027
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bundang CHA Medical Center
Seongnam-si, Gyeonggi-do, South Korea, 13496